The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...

The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...

The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.

The FDA suggests that prescribed users also reduce their calorie intake and increase their exercise The weight loss drug ...

Eli Lilly reported a 27% year-to-date revenue growth in 2024 when compared against 2023. The revenue increase is mostly attributed to the sales-growth performance of Mounjaro & Zepbound ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

The drop wiped out €90bn in market valuation, leading to a 16% decline in year-to-date performance for Europe's largest company. The Danish pharmaceutical giant said in a press release that the ...

We believe VK2735's clinical results to-date suggest a differentiated profile ... and is currently marketed in various dosage strengths and forms as Mounjaro® and Zepbound®. About Viking Therapeutics, ...

Current Target Price: $1040 Joseph Bonner, CFA -- Netflix has developed from upstart Hollywood outsider to being the central player in long-form streaming video, what has now become the future of the ...

Semaglutide and tirzepatide are both glucagon-like peptide-1 receptor agonists, known as GLP-1s, that work by telling your body that you just ate, triggering it to release more insulin and slowing ...